Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Medicenna Therapeutics Corp (MDNA.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 24,006
  • Shares Outstanding, K 28,578
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,465 K
  • 60-Month Beta 2.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.60
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings -0.07 on 12/31/18
  • Next Earnings Date 02/12/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.67 +23.88%
on 03/08/19
0.91 -8.79%
on 02/20/19
-0.08 (-8.79%)
since 02/19/19
3-Month
0.67 +23.88%
on 03/08/19
0.97 -14.43%
on 01/08/19
unch (unch)
since 12/19/18
52-Week
0.67 +23.88%
on 03/08/19
2.30 -63.91%
on 10/18/18
-1.12 (-57.44%)
since 03/19/18

Most Recent Stories

More News
Medicenna Reports Third Quarter Fiscal 2019 Financial Results

TORONTO and HOUSTON, TX , Feb. 14, 2019  /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today...

MDNAF : 0.6117 (+13.55%)
MDNA.TO : 0.83 (+2.47%)
Medicenna Reports Third Quarter Fiscal 2019 Financial Results

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and nine months ended December...

MDNA.TO : 0.83 (+2.47%)
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55

Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients

MDNAF : 0.6117 (+13.55%)
MDNA.TO : 0.83 (+2.47%)
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55

Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients

MDNA.TO : 0.83 (+2.47%)
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109

Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors

MDNA.TO : 0.83 (+2.47%)
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109

Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors

MDNAF : 0.6117 (+13.55%)
MDNA.TO : 0.83 (+2.47%)
Pacific Neuroscience Institute, Nationwide Site Leader of the MDNA55 Clinical Trial, Offers Final Enrollment for Glioblastoma Patients

The Pacific Brain Tumor Center at Pacific Neuroscience Institute, in collaboration with the John Wayne Cancer Institute at Providence Saint John's Health Center, is the leading enrollment site for the...

MDNA.TO : 0.83 (+2.47%)
Preliminary Results on MDNA55 and MDNA109 to be Presented at the Immuno-Oncology 360° Conference

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced two presentations at the Immuno-Oncology 360° Conference...

MDNA.TO : 0.83 (+2.47%)
Preliminary Results on MDNA55 and MDNA109 to be Presented at the Immuno-Oncology 360° Conference

TORONTO and HOUSTON , Jan. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced...

MDNAF : 0.6117 (+13.55%)
MDNA.TO : 0.83 (+2.47%)
Medicenna Receives US$1.2 Million Non-Dilutive Grant Payment

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$1,224,540 (approximately, CD$1.6M)...

MDNA.TO : 0.83 (+2.47%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Steady.

See More Share

Key Turning Points

2nd Resistance Point 0.86
1st Resistance Point 0.85
Last Price 0.83
1st Support Level 0.82
2nd Support Level 0.80

See More

52-Week High 2.30
Fibonacci 61.8% 1.68
Fibonacci 50% 1.49
Fibonacci 38.2% 1.29
Last Price 0.83
52-Week Low 0.67

See More

Business Summary

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically...

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar